Abstract
Decision makers are interested in measuring the costs and benefits of various interventions, and sometimes they are presented with the average costs and benefits of alternative interventions and asked to compare these. Usually a newer intervention is being compared with an existing one, and the most appropriate comparison is not of average costs (and benefits) but of the extra--or marginal--costs (and benefits) of the new intervention. Reanalysis of the cost effectiveness ratio of biochemical screening of all women for Down's syndrome compared with age based screening shows that the marginal cost effectiveness of biochemical screening is 47,786 pounds, compared with an average cost effectiveness of 37,591 pounds. It may sometimes be difficult or costly to calculate marginal costs and benefits, but this should be done whenever possible.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Hollingworth W., Todd C., Parker M., Roberts J. A., Williams R. Cost analysis of early discharge after hip fracture. BMJ. 1993 Oct 9;307(6909):903–906. doi: 10.1136/bmj.307.6909.903. [DOI] [PMC free article] [PubMed] [Google Scholar]
- McGhee S. M., McInnes G. T., Hedley A. J., Murray T. S., Reid J. L. Coordinating and standardizing long-term care: evaluation of the west of Scotland shared-care scheme for hypertension. Br J Gen Pract. 1994 Oct;44(387):441–445. [PMC free article] [PubMed] [Google Scholar]
- Neuhauser D., Lewicki A. M. What do we gain from the sixth stool guaiac? N Engl J Med. 1975 Jul 31;293(5):226–228. doi: 10.1056/NEJM197507312930504. [DOI] [PubMed] [Google Scholar]
- Piggott M., Wilkinson P., Bennett J. Implementation of an antenatal serum screening programme for Down's syndrome in two districts (Brighton and Eastbourne). The Brighton and Eastbourne Down's Syndrome Screening Group. J Med Screen. 1994 Jan;1(1):45–49. doi: 10.1177/096914139400100109. [DOI] [PubMed] [Google Scholar]
- Wald N. J., Kennard A., Densem J. W., Cuckle H. S., Chard T., Butler L. Antenatal maternal serum screening for Down's syndrome: results of a demonstration project. BMJ. 1992 Aug 15;305(6850):391–394. doi: 10.1136/bmj.305.6850.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Whynes D. K., Walker A. R. On approximations in treatment costing. Health Econ. 1995 Jan-Feb;4(1):31–39. doi: 10.1002/hec.4730040104. [DOI] [PubMed] [Google Scholar]
- Williams A. The cost-benefit approach. Br Med Bull. 1974 Sep;30(3):252–256. doi: 10.1093/oxfordjournals.bmb.a071211. [DOI] [PubMed] [Google Scholar]